Skip to content

Effect of Dextrose Injection in Rotator Cuff Tendinopathy of The Shoulder

A Comparative Study of the Effect of Two Concentrations of Dextrose Injection (12.5% And 25%) on Pain and Function of Patients with Rotator Cuff Tendinopathy of The Shoulder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230821059204N2
Enrollment
66
Registered
2023-10-12
Start date
2023-10-22
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator cuff tendinopathy of the shoulder. Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder

Interventions

Intervention 1: Intervention group 1: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension
in the second week includes external rotation at zero degrees
In the third week, it includes internal rotation at 0 degrees, and in the fourth week, it includes boat movement at 45 degrees, boat movement at 90 degrees, anterior shoulder stretching and trunk stre

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults (over 20 years) Chronic shoulder pain for more than six months Shoulder ultrasound of the supraspinatus tendon showing chronic tendinopathy such as a tear or tendinosis The average intensity of shoulder pain is more than 3 points on the ten-point Visual Analog Scale (VAS) Agreeing and complying with our study protocol The possibility of signing an informed consent form

Exclusion criteria

Exclusion criteria: Associated with adhesive capsulitis and limited range of motion of the shoulder Shoulder joint replacement Shoulder surgery or arthroscopy of the injured shoulder within the past year Injection of steroid, hyaluronic acid or platelet-rich plasma or any type of prolotherapy injection in the shoulder joint within the last three months Neurological disease that causes weakness on the affected side Impaired cognitive function and inability to complete the questionnaire Concurrent participation in another clinical trial

Design outcomes

Primary

MeasureTime frame
Average score in the Shoulder Pain and Disability Index (SPADI) of the injured shoulder. Timepoint: At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention. Method of measurement: The Shoulder Pain and Disability Index (SPADI) is a self-administered assessment tool used to measure shoulder pain and disability. It has five pain items and eight disability items measured on the Visual Analogue Score. Pain and disability subscales are calculated as the mean of the corresponding items on a 0-100 scale, with the highest score indicating the most severe pain and disability. In this study, the total outcome score used for statistical analysis will be calculated as the sum of pain and disability subscales.

Secondary

MeasureTime frame
Active range of motion of the shoulder. Timepoint: At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention. Method of measurement: Active shoulder range of motion, i.e., forward flexion, internal rotation, external rotation, and abduction in standing position, will be assessed using a goniometer. Patients will move their shoulders slowly until they reach an angle at which pain is felt, and this movement will be performed three times to record the average value of the angle.;Supraspinatus tendon thickness. Timepoint: At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention. Method of measurement: Using ultrasound, the maximum thickness of the supraspinatus tendon will be measured in millimeters.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHanieh Ahmadi

Mazandaran University of Medical Sciences

H.ahmadi@mazums.ac.ir+98 11 3336 6552

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026